Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohns disease

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1891-1897

  Di Sabatino, Antonio ^a   Biancheri, Paolo ^a   Piconese, Silvia ^b   Rosado, M Manuela ^c   Ardizzone, Sandro ^d   Rovedatti, Laura ^a   Ubezio, Cristina ^a   Massari, Alessandro ^a   Sampietro, Gianluca M ^d   Foschi, Diego ^e   Porro, Gabriele Bianchi ^d   Colombo, Mario P ^b   Carsetti, Rita ^c   MacDonald, Thomas T ^e   Corazza, Gino R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Foxp3; IL 10; suppression assay; TNF ?

Indexed keywords

INFLIXIMAB; INTERLEUKIN 10; MESALAZINE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CROHN DISEASE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTERLEUKIN-10; LYMPHOCYTE COUNT; MALE; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 78249240373     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21271     Document Type: Article

References (33)

1. O'Garra A, Vieira P,. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004; 10: 801-805.
2. Izcue A, Coombes JL, Powrie F,. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009; 27: 313-338.
3. Barnes MJ, Powrie F,. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009; 31: 401-411.
4. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198; 1875-1886.
5. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182: 18-32.
6. Bach JF,. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003; 3: 189-198.
7. Sakaguchi S,. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22: 531-562.
8. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004; 200: 277-285.
9. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005; 174: 164-173.
10. Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2006; 27: 110-118.
11. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199: 971-979.
12. bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004; 173: 3119-3130.
13. Bouma G, Strober W,. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003; 3: 521-533.
14. Singh B, Read S, Asseman C, et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev. 2001; 182: 190-200.
15. Fantini MC, Becker C, Tubbe I, et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006; 55: 671-680.
16. +CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005; 128: 1868-1878.
17. Saruta M, Yu QT, Fleshner PR, et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohns disease. Clin Immunol. 2007; 125: 281-290.
18. Chamouard P, Monneaux F, Richert Z, et al. Diminution of circulating CD4+CD25 high T cells in nave Crohns disease. Dig Dis Sci. 2009; 54: 2084-2093.
19. Papadakis KA, Targan SR,. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51: 289-298.
20. hi T-regulatory cells. Blood. 2006; 108: 253-261.
21. Papadakis KA, Targan SR,. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000; 119: 1148-1157.
22. Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009; 10: 1178-1184.
23. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohns disease activity index: National Cooperative Crohns Disease Study. Gastroenterology. 1976; 70: 439-444.
24. Irvine EJ,. Usual therapy improves perianal Crohns disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995; 20: 27-32.
25. Di Sabatino A, Pickard KM, Rampton D, et al. Blockade of transforming growth factor-β up-regulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut. 2008; 57: 605-612.
26. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999; 190: 995-1004.
27. Horwitz DA, Zheng SG, Gray JD,. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008; 29: 429-435.
28. Li Z, Bullens DM, Vermeire S, et al. New mechanism of action for anti-TNF therapy in IBD: induction of FOXP3+CD4+CD25+ and FOXP3+CD4+CD25-T cells in Crohns disease and ulcerative colitis. Gastroenterology. 2008; 134 (suppl 1): A507.
29. Ricciardelli I, Lindley KJ, Londei M, et al. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohns disease. Immunology. 2008; 125: 178-183.
30. Nadkarni S, Mauri C, Ehrenstein MR,. Anti-TNF-? therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med. 2007; 204: 33-39.
31. Green EA, Gorelik L, McGregor CM, et al. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S A. 2003; 100: 10878-10883.
32. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 2002; 8: 1024-1032.
33. Zhang X, Koldzic DN, Izikson L, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol. 2004; 16: 249-256.